Science Press Releases
SEE OTHER BRANDS

Informing on science news in the world

Science Press Releases: Press Releases

Browse our comprehensive archive of press releases by date.
Select a specific day to access all press releases published on Science Press Releases.

Press releases published on June 20, 2025

Actuate Therapeutics Reports Positive Biomarker and Machine Learning Data from Phase 2 Elraglusib Trial in First-Line Treatment of Metastatic Pancreatic Cancer at ASCO

Actuate Therapeutics Reports Positive Biomarker and Machine Learning Data from Phase 2 Elraglusib Trial in First-Line Treatment of Metastatic Pancreatic Cancer at ASCO

CHICAGO and FORT WORTH, Texas, June 20, 2025 (GLOBE NEWSWIRE) -- Actuate Therapeutics, Inc. (NASDAQ: ACTU) (“Actuate” or the “Company”), a clinical-stage biopharmaceutical company focused on developing therapies for the treatment of high-impact, difficult- …

VivoPower Closes First Phase of US$121 Million Private Placement

VivoPower Closes First Phase of US$121 Million Private Placement

LONDON, June 20, 2025 (GLOBE NEWSWIRE) -- VivoPower International PLC (NASDAQ: VVPR) (“VivoPower” or the “Company”) today announced that it has closed the first phase of the previously announced US$121 million investment round led by His Royal Highness …

ideal-finance.com Partners with International Financial Giants to Build a New Mechanism for Global Asset Cross-Border Circulation

ideal-finance.com Partners with International Financial Giants to Build a New Mechanism for Global Asset Cross-Border Circulation

New York, USA, June 20, 2025 (GLOBE NEWSWIRE) -- The leading global digital finance platform ideal-finance.com has announced deep strategic collaborations with several top international banks and multinational financial institutions to jointly promote the …

Journey Medical Corporation Announces Emrosi™ Data Analysis to be Presented at the Society of Dermatology Physician Associates (SDPA) 2025 Annual Summer Dermatology Conference

Journey Medical Corporation Announces Emrosi™ Data Analysis to be Presented at the Society of Dermatology Physician Associates (SDPA) 2025 Annual Summer Dermatology Conference

SCOTTSDALE, Ariz., June 20, 2025 (GLOBE NEWSWIRE) -- Journey Medical Corporation (Nasdaq: DERM) (“Journey Medical” or “the Company”, “we”, or “our”), a commercial-stage pharmaceutical company that primarily focuses on selling and marketing U.S. Food and …

Volatus LIFE Offering Financing Oversubscribed and Upsized to $5,000,000

Volatus LIFE Offering Financing Oversubscribed and Upsized to $5,000,000

Not for distribution to United States newswire services or for dissemination in the United States. TORONTO, June 20, 2025 (GLOBE NEWSWIRE) -- Volatus Aerospace Inc. (TSXV:FLT) (OTCQX:TAKOF) (Frankfurt: ABB) (“Volatus” or the “Company”) is pleased to …

ideal-finance.com Achieves Breakthrough in Technical Strength, Establishing a Global Benchmark with Full-Stack Self-Developed Financial System

ideal-finance.com Achieves Breakthrough in Technical Strength, Establishing a Global Benchmark with Full-Stack Self-Developed Financial System

New York, USA, June 20, 2025 (GLOBE NEWSWIRE) -- In the context of rapid globalization in fintech, ideal-finance.com has once again set a new industry standard by announcing the full launch of its next-generation trading system, developed entirely in-house …

Martini Market Fills Over 40% of Presale Allocation Within 24 Hours of Launch on XRP Ledger

Martini Market Fills Over 40% of Presale Allocation Within 24 Hours of Launch on XRP Ledger

DUBAI, United Arab Emirates, June 20, 2025 (GLOBE NEWSWIRE) -- Martini Market, a decentralized prediction market protocol built on the XRP Ledger (XRPL), has announced that over 40% of its $MRT token presale allocation has been filled within the first 24 …

SpringWorks Therapeutics Receives Positive CHMP Opinion for Nirogacestat for the Treatment of Adults with Desmoid Tumors

SpringWorks Therapeutics Receives Positive CHMP Opinion for Nirogacestat for the Treatment of Adults with Desmoid Tumors

– If approved, nirogacestat will be the first and only therapy with marketing authorization in the EU for the treatment of desmoid tumors – – Decision from European Commission expected in the third quarter of 2025 – STAMFORD, Conn., June 20, 2025 (GLOBE …

Bilibili Inc. Announces Results of Annual General Meeting

Bilibili Inc. Announces Results of Annual General Meeting

SHANGHAI, June 20, 2025 (GLOBE NEWSWIRE) -- Bilibili Inc. (“Bilibili” or the “Company”) (Nasdaq: BILI and HKEX: 9626), an iconic brand and a leading video community for young generations in China, today announced that each of the proposed resolutions (the …

Soleno Therapeutics Announces Multiple Presentations at the 2025 United in Hope: International Prader-Willi Syndrome Conference

Soleno Therapeutics Announces Multiple Presentations at the 2025 United in Hope: International Prader-Willi Syndrome Conference

REDWOOD CITY, Calif., June 20, 2025 (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc. (Soleno) (NASDAQ: SLNO), a biopharmaceutical company developing novel therapeutics for the treatment of rare diseases, today announced one oral and six poster presentations …

BullFrog AI’s Dr. Juan Felipe Beltrán to Highlight Advanced AI Strategies in Bioinformatics at XTalks Webinar

BullFrog AI’s Dr. Juan Felipe Beltrán to Highlight Advanced AI Strategies in Bioinformatics at XTalks Webinar

GAITHERSBURG, Md., June 20, 2025 (GLOBE NEWSWIRE) -- BullFrog AI Holdings, Inc. (NASDAQ: BFRG; BFRGW) ("BullFrog AI" or the "Company"), a technology-enabled drug development company using artificial intelligence (AI) and machine learning to enable the …

Telix Precision Medicine Announces AlFluor Radiochemistry Platform

Telix Precision Medicine Announces AlFluor Radiochemistry Platform

MELBOURNE, Australia and INDIANAPOLIS, June 20, 2025 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX, “Telix”, “the Company”) today announces it has launched a novel PET1 radiochemistry solution based on 18F-aluminium fluoride (AlF …

Aptose and Hanmi Enter New Loan Agreement to Advance Development of Tuspetinib in Triplet Therapy for AML

Aptose and Hanmi Enter New Loan Agreement to Advance Development of Tuspetinib in Triplet Therapy for AML

SAN DIEGO and TORONTO, June 20, 2025 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. ("Aptose" or the "Company") (TSX: APS; OTC: APTOF), a clinical-stage precision oncology company developing a tuspetinib (TUS) based triple drug frontline therapy to treat …

Firefly Neuroscience Researchers Uncover Powerful New Way of Objectively Measuring SCD, MCI, and Dementia in Alzheimer’s Patients

Firefly Neuroscience Researchers Uncover Powerful New Way of Objectively Measuring SCD, MCI, and Dementia in Alzheimer’s Patients

– Research supports combined use of EEG/ERP and vMRI for accurate differential diagnosis of SCD, MCI and dementia – – Also highlights that low-cost and off-based EEG/ERP alone also delivered reasonably accurate predictions of cognitive impairment typology …

Onco360 Has Been Selected as a National Specialty Pharmacy Partner for QINLOCK® (ripretinib)

Onco360 Has Been Selected as a National Specialty Pharmacy Partner for QINLOCK® (ripretinib)

LOUISVILLE, Ky., June 20, 2025 (GLOBE NEWSWIRE) -- Onco360®, the nation’s leading independent specialty pharmacy, has been selected as a pharmacy partner by Deciphera Pharmaceuticals, LLC for QINLOCK® (ripretinib), which has been approved by the U.S. Food …

Axsome Therapeutics Champions Brain Health During Alzheimer's & Brain Awareness Month

Axsome Therapeutics Champions Brain Health During Alzheimer's & Brain Awareness Month

NEW YORK, June 20, 2025 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company leading a new era in the treatment of central nervous system (CNS) disorders, today is joining with the Alzheimer’s disease advocacy community …

Madrigal Receives Positive CHMP Opinion for Resmetirom (Rezdiffra™) for the Treatment of MASH with Moderate to Advanced Liver Fibrosis

Madrigal Receives Positive CHMP Opinion for Resmetirom (Rezdiffra™) for the Treatment of MASH with Moderate to Advanced Liver Fibrosis

Positive recommendation based on resmetirom’s favorable profile including positive results from the pivotal Phase 3 MAESTRO-NASH trial European Commission decision expected in August 2025; if approved, resmetirom will be the first medication for people …

CHMP recommends third indication for darolutamide for patients with advanced prostate cancer

CHMP recommends third indication for darolutamide for patients with advanced prostate cancer

ORION CORPORATION PRESS RELEASE 20 JUNE 2025 at 13.30 EEST           CHMP recommends third indication for darolutamide for patients with advanced prostate cancer CHMP adopts positive opinion for the marketing authorisation of darolutamide in combination …

Euroopan lääkeviraston ihmislääkekomitealta (CHMP) myönteinen lausunto darolutamidin kolmannelle käyttöaiheelle edennyttä eturauhassyöpää sairastavien potilaiden hoidossa

Euroopan lääkeviraston ihmislääkekomitealta (CHMP) myönteinen lausunto darolutamidin kolmannelle käyttöaiheelle edennyttä eturauhassyöpää sairastavien potilaiden hoidossa

ORION OYJ LEHDISTÖTIEDOTE 20.6.2025 klo 13.30          Euroopan lääkeviraston ihmislääkekomitealta (CHMP) myönteinen lausunto darolutamidin kolmannelle käyttöaiheelle edennyttä eturauhassyöpää sairastavien potilaiden hoidossa CHMP suosittaa myyntiluvan …

Bombardier Defense Receives Firm Order for Two Global 6500 Aircraft from Saab

Bombardier Defense Receives Firm Order for Two Global 6500 Aircraft from Saab

The Bombardier Global 6500 aircraft, a proven platform providing range, speed, reliability and endurance, is an ideal fixed-wing solution for airborne special missions worldwide  The Global 6500 is the aircraft of choice for governments around the world …

Share us

on your social networks:
AGPs

Get the latest news on this topic.

SIGN UP FOR FREE TODAY

No Thanks

By signing to this email alert, you
agree to our Terms of Service